 Lisa Schilling
Concepts (306)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Periodicals as Topic | 11 | 2008 | 187 | 1.450 |
Why?
| | Decision Support Systems, Clinical | 2 | 2022 | 176 | 1.380 |
Why?
| | Electronic Health Records | 9 | 2022 | 809 | 1.190 |
Why?
| | Comparative Effectiveness Research | 4 | 2017 | 131 | 1.080 |
Why?
| | Data Mining | 2 | 2017 | 100 | 0.970 |
Why?
| | Information Storage and Retrieval | 7 | 2021 | 113 | 0.920 |
Why?
| | Publishing | 7 | 2007 | 128 | 0.870 |
Why?
| | Ultraviolet Rays | 6 | 2015 | 381 | 0.840 |
Why?
| | Urinary Tract Infections | 1 | 2023 | 135 | 0.840 |
Why?
| | Critical Pathways | 1 | 2022 | 79 | 0.820 |
Why?
| | Dermatology | 8 | 2021 | 88 | 0.760 |
Why?
| | Medical Informatics | 4 | 2021 | 97 | 0.720 |
Why?
| | Sunbathing | 2 | 2015 | 14 | 0.670 |
Why?
| | Internet | 10 | 2018 | 602 | 0.670 |
Why?
| | Skin Neoplasms | 7 | 2015 | 762 | 0.670 |
Why?
| | Hypertension | 5 | 2022 | 1199 | 0.670 |
Why?
| | Blood Pressure Determination | 1 | 2018 | 133 | 0.610 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2022 | 387 | 0.560 |
Why?
| | Biomedical Research | 5 | 2021 | 600 | 0.540 |
Why?
| | Safety-net Providers | 2 | 2019 | 96 | 0.540 |
Why?
| | Attitude of Health Personnel | 4 | 2016 | 990 | 0.500 |
Why?
| | Patient Outcome Assessment | 1 | 2016 | 123 | 0.500 |
Why?
| | Melanoma | 4 | 2021 | 664 | 0.480 |
Why?
| | Health Maintenance Organizations | 2 | 2011 | 96 | 0.480 |
Why?
| | Myotonic Dystrophy | 1 | 2013 | 5 | 0.480 |
Why?
| | Foot Deformities, Congenital | 1 | 2013 | 7 | 0.480 |
Why?
| | Contracture | 1 | 2013 | 23 | 0.470 |
Why?
| | Surveys and Questionnaires | 10 | 2022 | 4684 | 0.470 |
Why?
| | Spinal Diseases | 1 | 2013 | 47 | 0.460 |
Why?
| | Benchmarking | 2 | 2011 | 172 | 0.460 |
Why?
| | Quality Indicators, Health Care | 3 | 2010 | 295 | 0.460 |
Why?
| | Primary Health Care | 4 | 2022 | 1539 | 0.450 |
Why?
| | Delivery of Health Care, Integrated | 2 | 2018 | 230 | 0.450 |
Why?
| | Peer Review, Research | 3 | 2007 | 35 | 0.430 |
Why?
| | Beauty Culture | 4 | 2005 | 13 | 0.420 |
Why?
| | Medication Adherence | 1 | 2016 | 554 | 0.390 |
Why?
| | Humans | 63 | 2023 | 118251 | 0.380 |
Why?
| | Total Quality Management | 1 | 2010 | 61 | 0.380 |
Why?
| | Patient-Centered Care | 1 | 2016 | 493 | 0.380 |
Why?
| | Databases, Bibliographic | 3 | 2004 | 28 | 0.370 |
Why?
| | Transgender Persons | 2 | 2023 | 135 | 0.370 |
Why?
| | Information Management | 2 | 2012 | 15 | 0.370 |
Why?
| | Evidence-Based Medicine | 3 | 2005 | 690 | 0.360 |
Why?
| | Quality Improvement | 3 | 2019 | 962 | 0.340 |
Why?
| | Fractures, Bone | 1 | 2013 | 376 | 0.330 |
Why?
| | Leadership | 1 | 2011 | 310 | 0.330 |
Why?
| | Information Dissemination | 1 | 2010 | 193 | 0.320 |
Why?
| | Models, Statistical | 1 | 2012 | 633 | 0.320 |
Why?
| | Tretinoin | 1 | 2009 | 116 | 0.320 |
Why?
| | Medical Record Linkage | 3 | 2014 | 53 | 0.300 |
Why?
| | United States | 23 | 2022 | 12488 | 0.300 |
Why?
| | Internship and Residency | 4 | 2006 | 1005 | 0.300 |
Why?
| | Internal Medicine | 3 | 2006 | 215 | 0.300 |
Why?
| | Cause of Death | 1 | 2009 | 379 | 0.290 |
Why?
| | Anticholesteremic Agents | 2 | 2005 | 131 | 0.290 |
Why?
| | Access to Information | 1 | 2006 | 51 | 0.280 |
Why?
| | Disclosure | 1 | 2007 | 102 | 0.280 |
Why?
| | Clofibric Acid | 1 | 2005 | 1 | 0.280 |
Why?
| | Databases, Factual | 5 | 2021 | 1196 | 0.270 |
Why?
| | Archives | 1 | 2004 | 5 | 0.260 |
Why?
| | Libraries, Digital | 1 | 2004 | 4 | 0.260 |
Why?
| | Middle Aged | 19 | 2023 | 27510 | 0.260 |
Why?
| | Adolescent | 18 | 2023 | 18364 | 0.250 |
Why?
| | Spain | 5 | 2021 | 34 | 0.250 |
Why?
| | Comorbidity | 7 | 2022 | 1516 | 0.250 |
Why?
| | Gemfibrozil | 2 | 2006 | 10 | 0.250 |
Why?
| | Lovastatin | 2 | 2006 | 27 | 0.250 |
Why?
| | Hospitalization | 6 | 2022 | 1778 | 0.240 |
Why?
| | Young Adult | 10 | 2023 | 10731 | 0.230 |
Why?
| | Legislation as Topic | 1 | 2003 | 4 | 0.230 |
Why?
| | Aged | 14 | 2023 | 19594 | 0.220 |
Why?
| | Programming Languages | 2 | 2021 | 23 | 0.220 |
Why?
| | Anticarcinogenic Agents | 1 | 2003 | 68 | 0.220 |
Why?
| | Patient Acceptance of Health Care | 3 | 2023 | 683 | 0.210 |
Why?
| | Adult | 16 | 2023 | 31324 | 0.210 |
Why?
| | Computer Communication Networks | 1 | 2021 | 33 | 0.200 |
Why?
| | Female | 24 | 2023 | 61261 | 0.200 |
Why?
| | Drug Repositioning | 1 | 2021 | 13 | 0.200 |
Why?
| | Confidentiality | 1 | 2021 | 66 | 0.200 |
Why?
| | Perception | 1 | 2023 | 314 | 0.200 |
Why?
| | Influenza, Human | 3 | 2021 | 553 | 0.190 |
Why?
| | Natural Language Processing | 1 | 2021 | 71 | 0.190 |
Why?
| | Sexual and Gender Minorities | 1 | 2023 | 136 | 0.190 |
Why?
| | Computational Biology | 1 | 2004 | 541 | 0.190 |
Why?
| | Faculty, Medical | 1 | 2003 | 252 | 0.180 |
Why?
| | Artificial Intelligence | 1 | 2021 | 137 | 0.180 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2021 | 360 | 0.180 |
Why?
| | Antineoplastic Agents | 2 | 2009 | 1967 | 0.180 |
Why?
| | Pandemics | 4 | 2021 | 1338 | 0.170 |
Why?
| | Database Management Systems | 2 | 2012 | 50 | 0.170 |
Why?
| | Aged, 80 and over | 7 | 2021 | 6541 | 0.170 |
Why?
| | Language | 1 | 2021 | 271 | 0.170 |
Why?
| | Occupational Health | 1 | 2021 | 172 | 0.170 |
Why?
| | Student Health Services | 1 | 2018 | 16 | 0.160 |
Why?
| | Patient Portals | 1 | 2018 | 31 | 0.160 |
Why?
| | Cohort Studies | 7 | 2021 | 5078 | 0.160 |
Why?
| | Hypersensitivity | 1 | 2021 | 270 | 0.150 |
Why?
| | Male | 21 | 2021 | 57474 | 0.150 |
Why?
| | Health Plan Implementation | 1 | 2019 | 132 | 0.150 |
Why?
| | Randomized Controlled Trials as Topic | 4 | 2009 | 1237 | 0.150 |
Why?
| | Asthma | 2 | 2022 | 2143 | 0.150 |
Why?
| | Republic of Korea | 3 | 2021 | 26 | 0.150 |
Why?
| | Algorithms | 3 | 2021 | 1522 | 0.150 |
Why?
| | Authorship | 2 | 2007 | 35 | 0.150 |
Why?
| | Palliative Care | 1 | 2022 | 630 | 0.140 |
Why?
| | Health Personnel | 1 | 2021 | 578 | 0.130 |
Why?
| | Advance Care Planning | 1 | 2018 | 191 | 0.130 |
Why?
| | Education, Medical | 2 | 2011 | 239 | 0.130 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 347 | 0.130 |
Why?
| | Coronavirus Infections | 1 | 2020 | 338 | 0.130 |
Why?
| | Health Education | 1 | 2018 | 317 | 0.130 |
Why?
| | Review Literature as Topic | 2 | 2006 | 68 | 0.130 |
Why?
| | Health Care Surveys | 2 | 2016 | 544 | 0.130 |
Why?
| | Hyperlipidemias | 1 | 2016 | 127 | 0.130 |
Why?
| | Practice Patterns, Physicians' | 2 | 2016 | 1197 | 0.130 |
Why?
| | Prevalence | 4 | 2021 | 2321 | 0.130 |
Why?
| | Trichotillomania | 1 | 2014 | 7 | 0.120 |
Why?
| | Decision Support Techniques | 1 | 2018 | 364 | 0.120 |
Why?
| | Anti-Bacterial Agents | 1 | 2023 | 1514 | 0.120 |
Why?
| | Early Detection of Cancer | 1 | 2018 | 360 | 0.120 |
Why?
| | Communication | 1 | 2020 | 754 | 0.120 |
Why?
| | Affective Symptoms | 1 | 2014 | 50 | 0.120 |
Why?
| | Retrospective Studies | 4 | 2021 | 12929 | 0.120 |
Why?
| | Diabetes Mellitus | 1 | 2022 | 939 | 0.120 |
Why?
| | Models, Theoretical | 1 | 2017 | 554 | 0.110 |
Why?
| | Emergency Service, Hospital | 1 | 2023 | 1848 | 0.110 |
Why?
| | France | 2 | 2021 | 35 | 0.110 |
Why?
| | Obesity | 2 | 2022 | 2715 | 0.100 |
Why?
| | Medical Records Systems, Computerized | 1 | 2012 | 91 | 0.100 |
Why?
| | Colorectal Neoplasms | 1 | 2018 | 628 | 0.100 |
Why?
| | Curriculum | 2 | 2011 | 908 | 0.100 |
Why?
| | Thalassemia | 1 | 2011 | 7 | 0.100 |
Why?
| | Child, Preschool | 4 | 2021 | 9448 | 0.100 |
Why?
| | Planning Techniques | 1 | 2010 | 14 | 0.100 |
Why?
| | Ambulatory Care | 2 | 2006 | 480 | 0.100 |
Why?
| | Child | 7 | 2021 | 19033 | 0.100 |
Why?
| | Organizational Objectives | 1 | 2010 | 74 | 0.090 |
Why?
| | Quality Assurance, Health Care | 2 | 2010 | 324 | 0.090 |
Why?
| | Disaster Planning | 1 | 2011 | 76 | 0.090 |
Why?
| | Cost Savings | 1 | 2010 | 77 | 0.090 |
Why?
| | Heart Diseases | 1 | 2013 | 340 | 0.090 |
Why?
| | Health Records, Personal | 1 | 2010 | 24 | 0.090 |
Why?
| | Safety Management | 1 | 2010 | 109 | 0.090 |
Why?
| | Efficiency, Organizational | 1 | 2010 | 126 | 0.090 |
Why?
| | Organizational Culture | 1 | 2010 | 121 | 0.090 |
Why?
| | Organizational Innovation | 1 | 2010 | 138 | 0.090 |
Why?
| | Emotions | 1 | 2014 | 494 | 0.090 |
Why?
| | Infant | 3 | 2021 | 8254 | 0.090 |
Why?
| | Health Services Research | 1 | 2012 | 384 | 0.080 |
Why?
| | Administration, Topical | 1 | 2009 | 141 | 0.080 |
Why?
| | Codes of Ethics | 1 | 2008 | 16 | 0.080 |
Why?
| | Human Experimentation | 1 | 2008 | 12 | 0.080 |
Why?
| | Continuity of Patient Care | 1 | 2010 | 262 | 0.080 |
Why?
| | Age Factors | 3 | 2020 | 2990 | 0.080 |
Why?
| | Neoplasms | 1 | 2021 | 2160 | 0.080 |
Why?
| | Self-Evaluation Programs | 1 | 2007 | 6 | 0.070 |
Why?
| | Scientific Misconduct | 1 | 2007 | 10 | 0.070 |
Why?
| | Lung Diseases | 1 | 2013 | 709 | 0.070 |
Why?
| | Public Health | 1 | 2011 | 447 | 0.070 |
Why?
| | Ethics, Research | 1 | 2007 | 31 | 0.070 |
Why?
| | Academic Medical Centers | 2 | 2021 | 422 | 0.070 |
Why?
| | Physician-Patient Relations | 2 | 2002 | 484 | 0.070 |
Why?
| | Bibliometrics | 1 | 2007 | 51 | 0.070 |
Why?
| | Students, Medical | 2 | 2011 | 311 | 0.070 |
Why?
| | Smallpox Vaccine | 1 | 2006 | 23 | 0.070 |
Why?
| | Hypolipidemic Agents | 1 | 2006 | 86 | 0.070 |
Why?
| | Knowledge | 1 | 2006 | 55 | 0.070 |
Why?
| | Family Practice | 1 | 2010 | 433 | 0.070 |
Why?
| | Vaccination | 2 | 2021 | 1218 | 0.070 |
Why?
| | Medical Staff, Hospital | 1 | 2006 | 73 | 0.070 |
Why?
| | Clinical Clerkship | 1 | 2007 | 98 | 0.070 |
Why?
| | Research Design | 2 | 2014 | 961 | 0.070 |
Why?
| | Editorial Policies | 1 | 2004 | 46 | 0.060 |
Why?
| | Taxes | 1 | 2003 | 9 | 0.060 |
Why?
| | Teaching | 1 | 2006 | 235 | 0.060 |
Why?
| | Risk Factors | 3 | 2021 | 8958 | 0.060 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2018 | 1183 | 0.060 |
Why?
| | Cross-Sectional Studies | 5 | 2022 | 4521 | 0.060 |
Why?
| | Intensive Care Units | 1 | 2007 | 633 | 0.060 |
Why?
| | Medical Staff | 1 | 2002 | 16 | 0.060 |
Why?
| | Testosterone Congeners | 1 | 2022 | 8 | 0.060 |
Why?
| | Chemoprevention | 1 | 2003 | 89 | 0.050 |
Why?
| | Documentation | 1 | 2004 | 170 | 0.050 |
Why?
| | Gender Identity | 1 | 2023 | 102 | 0.050 |
Why?
| | Meta-Analysis as Topic | 1 | 2003 | 164 | 0.050 |
Why?
| | Medical Oncology | 1 | 2004 | 229 | 0.050 |
Why?
| | Smoking Prevention | 1 | 2003 | 150 | 0.050 |
Why?
| | Fibric Acids | 1 | 2021 | 2 | 0.050 |
Why?
| | Canada | 1 | 2003 | 338 | 0.050 |
Why?
| | Common Data Elements | 1 | 2021 | 9 | 0.050 |
Why?
| | Ceftriaxone | 1 | 2021 | 17 | 0.050 |
Why?
| | Administrative Claims, Healthcare | 1 | 2021 | 22 | 0.050 |
Why?
| | Sepsis | 1 | 2007 | 531 | 0.050 |
Why?
| | Lopinavir | 1 | 2021 | 29 | 0.050 |
Why?
| | Germany | 1 | 2021 | 89 | 0.050 |
Why?
| | Fluoroquinolones | 1 | 2021 | 42 | 0.050 |
Why?
| | Gonadotropin-Releasing Hormone | 1 | 2022 | 193 | 0.050 |
Why?
| | Colorado | 5 | 2019 | 4178 | 0.050 |
Why?
| | Hydroxychloroquine | 1 | 2021 | 59 | 0.050 |
Why?
| | Enoxaparin | 1 | 2021 | 51 | 0.050 |
Why?
| | United Kingdom | 1 | 2021 | 234 | 0.050 |
Why?
| | Ambulatory Care Facilities | 1 | 2002 | 216 | 0.050 |
Why?
| | Ritonavir | 1 | 2021 | 70 | 0.050 |
Why?
| | China | 1 | 2021 | 175 | 0.050 |
Why?
| | United States Food and Drug Administration | 1 | 2021 | 174 | 0.050 |
Why?
| | Azithromycin | 1 | 2021 | 81 | 0.050 |
Why?
| | Age Distribution | 1 | 2021 | 358 | 0.050 |
Why?
| | Drug Combinations | 1 | 2021 | 291 | 0.050 |
Why?
| | Infant, Newborn | 2 | 2021 | 5230 | 0.050 |
Why?
| | Symptom Assessment | 1 | 2021 | 123 | 0.050 |
Why?
| | Medically Underserved Area | 1 | 2000 | 85 | 0.040 |
Why?
| | Complementary Therapies | 1 | 2000 | 71 | 0.040 |
Why?
| | Patient Satisfaction | 2 | 2002 | 609 | 0.040 |
Why?
| | Treatment Outcome | 3 | 2021 | 9319 | 0.040 |
Why?
| | Patient Participation | 1 | 2023 | 368 | 0.040 |
Why?
| | Narration | 1 | 2020 | 47 | 0.040 |
Why?
| | Estradiol | 1 | 2022 | 473 | 0.040 |
Why?
| | Safety | 1 | 2021 | 304 | 0.040 |
Why?
| | Managed Care Programs | 1 | 2000 | 135 | 0.040 |
Why?
| | Testosterone | 1 | 2022 | 350 | 0.040 |
Why?
| | Software Design | 1 | 2018 | 22 | 0.040 |
Why?
| | Sexual Behavior | 1 | 2023 | 435 | 0.040 |
Why?
| | Skin | 1 | 2003 | 657 | 0.040 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2021 | 980 | 0.040 |
Why?
| | Severity of Illness Index | 2 | 2019 | 2659 | 0.040 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2021 | 246 | 0.040 |
Why?
| | Datasets as Topic | 1 | 2019 | 101 | 0.040 |
Why?
| | Overweight | 1 | 2022 | 492 | 0.040 |
Why?
| | Occult Blood | 1 | 2018 | 27 | 0.040 |
Why?
| | Vitamin D | 1 | 2021 | 352 | 0.040 |
Why?
| | Physicians | 1 | 2006 | 792 | 0.040 |
Why?
| | Inpatients | 1 | 2021 | 387 | 0.040 |
Why?
| | Adrenal Cortex Hormones | 1 | 2021 | 517 | 0.040 |
Why?
| | Spiro Compounds | 1 | 1996 | 10 | 0.040 |
Why?
| | Fiber Optic Technology | 1 | 1997 | 19 | 0.040 |
Why?
| | Diagnosis, Differential | 1 | 2021 | 1379 | 0.040 |
Why?
| | Intracranial Pressure | 1 | 1997 | 53 | 0.040 |
Why?
| | Growth Hormone | 1 | 1996 | 107 | 0.040 |
Why?
| | Logistic Models | 1 | 2021 | 1896 | 0.030 |
Why?
| | Cooperative Behavior | 2 | 2011 | 401 | 0.030 |
Why?
| | Colonoscopy | 1 | 2018 | 208 | 0.030 |
Why?
| | United States Public Health Service | 1 | 2015 | 8 | 0.030 |
Why?
| | Internationality | 1 | 2016 | 152 | 0.030 |
Why?
| | Smoking | 1 | 2003 | 1478 | 0.030 |
Why?
| | Referral and Consultation | 1 | 2000 | 644 | 0.030 |
Why?
| | Sex Factors | 1 | 2020 | 1765 | 0.030 |
Why?
| | Neoplasms, Radiation-Induced | 2 | 2005 | 65 | 0.030 |
Why?
| | Antidepressive Agents | 1 | 2016 | 189 | 0.030 |
Why?
| | Monitoring, Physiologic | 1 | 1997 | 268 | 0.030 |
Why?
| | Insulin-Like Growth Factor I | 1 | 1996 | 285 | 0.030 |
Why?
| | Quality of Life | 2 | 2019 | 2355 | 0.030 |
Why?
| | Program Evaluation | 1 | 2019 | 838 | 0.030 |
Why?
| | Indoles | 1 | 1996 | 311 | 0.030 |
Why?
| | Clinical Competence | 3 | 2007 | 950 | 0.030 |
Why?
| | Delivery of Health Care | 1 | 2021 | 862 | 0.030 |
Why?
| | Prospective Studies | 2 | 2003 | 6443 | 0.030 |
Why?
| | Patient Education as Topic | 1 | 2018 | 696 | 0.030 |
Why?
| | Registries | 1 | 2021 | 1806 | 0.030 |
Why?
| | Data Collection | 2 | 2006 | 652 | 0.030 |
Why?
| | Antihypertensive Agents | 1 | 2016 | 436 | 0.030 |
Why?
| | Disease Progression | 1 | 2019 | 2477 | 0.030 |
Why?
| | Problem-Based Learning | 1 | 2011 | 82 | 0.020 |
Why?
| | Time Factors | 1 | 2021 | 6368 | 0.020 |
Why?
| | Schools, Medical | 1 | 2011 | 138 | 0.020 |
Why?
| | Health Surveys | 1 | 2011 | 453 | 0.020 |
Why?
| | Hypoglycemic Agents | 1 | 2016 | 1031 | 0.020 |
Why?
| | MEDLINE | 1 | 2007 | 24 | 0.020 |
Why?
| | Depression | 1 | 2016 | 1133 | 0.020 |
Why?
| | Bezafibrate | 1 | 2006 | 1 | 0.020 |
Why?
| | Clofibrate | 1 | 2006 | 4 | 0.020 |
Why?
| | Pravastatin | 1 | 2006 | 29 | 0.020 |
Why?
| | Heptanoic Acids | 1 | 2006 | 62 | 0.020 |
Why?
| | Bioterrorism | 1 | 2006 | 19 | 0.020 |
Why?
| | Simvastatin | 1 | 2006 | 65 | 0.020 |
Why?
| | Quality Control | 1 | 2006 | 155 | 0.020 |
Why?
| | Electronic Mail | 1 | 2006 | 55 | 0.020 |
Why?
| | Research Personnel | 1 | 2007 | 155 | 0.020 |
Why?
| | Guidelines as Topic | 1 | 2008 | 261 | 0.020 |
Why?
| | Outpatient Clinics, Hospital | 1 | 2006 | 79 | 0.020 |
Why?
| | Pyrroles | 1 | 2006 | 188 | 0.020 |
Why?
| | Animals | 1 | 2007 | 33152 | 0.020 |
Why?
| | Reproducibility of Results | 2 | 2006 | 2855 | 0.020 |
Why?
| | Hypermedia | 1 | 2004 | 1 | 0.020 |
Why?
| | Educational Measurement | 1 | 2007 | 289 | 0.020 |
Why?
| | Computers | 1 | 2004 | 64 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2011 | 2491 | 0.010 |
Why?
| | Beds | 1 | 2003 | 5 | 0.010 |
Why?
| | Education, Medical, Undergraduate | 1 | 2007 | 199 | 0.010 |
Why?
| | Interprofessional Relations | 1 | 2006 | 260 | 0.010 |
Why?
| | Odds Ratio | 1 | 2006 | 993 | 0.010 |
Why?
| | Professional Autonomy | 1 | 2002 | 25 | 0.010 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2016 | 2159 | 0.010 |
Why?
| | Pilot Projects | 1 | 2007 | 1405 | 0.010 |
Why?
| | Probability | 1 | 2002 | 302 | 0.010 |
Why?
| | Research | 1 | 2004 | 406 | 0.010 |
Why?
| | Incidence | 1 | 2006 | 2413 | 0.010 |
Why?
| | Outpatients | 1 | 2002 | 324 | 0.010 |
Why?
| | Software | 1 | 2004 | 566 | 0.010 |
Why?
| | Quality of Health Care | 1 | 2002 | 585 | 0.010 |
Why?
| | Evaluation Studies as Topic | 1 | 1997 | 181 | 0.010 |
Why?
| | Socioeconomic Factors | 1 | 2000 | 1121 | 0.010 |
Why?
| | Administration, Oral | 1 | 1996 | 753 | 0.010 |
Why?
| | Double-Blind Method | 1 | 1996 | 1683 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 1996 | 1937 | 0.010 |
Why?
| | Case-Control Studies | 1 | 1997 | 3156 | 0.010 |
Why?
| | Blood Glucose | 1 | 1996 | 1936 | 0.000 |
Why?
|
|
Schilling's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|